Mark Cuban

He's turning red, actually. So if you go to costplusdrugs.com and you put in Tadilafil, when it comes up, we show you our actual cost. And then we mark it up by 15%. And if you buy it via mail order, then we add $5 for a pharmacy fee to review everything and $5 for shipping and handling. The net result of that is, you guys have a general idea of what the price is now from all the ads.

You can buy a 90-pack of Tadilafil for about $9.90 plus shipping and handling. So for less than the price of a bag of M&Ms, you could put up a little cup or jar next to your bed of either M&Ms or Tadilafil.

You can buy a 90-pack of Tadilafil for about $9.90 plus shipping and handling. So for less than the price of a bag of M&Ms, you could put up a little cup or jar next to your bed of either M&Ms or Tadilafil.

be right back nine dollars for 90 days right we're like let's go that seems free it's an incredible deal so but you apply that to the 2500 drugs that we have and now all of a sudden you see what's wrong with these things called pharmacy benefit managers and the problem of an industry that's opaque and i'll give you another example There are drugs that are called specialty generics.

be right back nine dollars for 90 days right we're like let's go that seems free it's an incredible deal so but you apply that to the 2500 drugs that we have and now all of a sudden you see what's wrong with these things called pharmacy benefit managers and the problem of an industry that's opaque and i'll give you another example There are drugs that are called specialty generics.

And the only thing special about them, they're actually just pills, is that they were traditionally more expensive. So there's a drug called imatinib, which is a chemotherapy drug. If you just walk into a CVS, as an example, a big, big pharmacy, and you're a cash payer or a high deductible payer and you just needed it, They'll charge you anywhere from $200 to $2,000.

And the only thing special about them, they're actually just pills, is that they were traditionally more expensive. So there's a drug called imatinib, which is a chemotherapy drug. If you just walk into a CVS, as an example, a big, big pharmacy, and you're a cash payer or a high deductible payer and you just needed it, They'll charge you anywhere from $200 to $2,000.

You have no idea what you're going to pay. If you get it from Cost Plus Drugs, depending on the number and the strength, it might be $21 to $30. There's another drug, Droxodopa. One of my buddies came to me and said, I'm losing my insurance. They want to charge me, the pharmacy wants to charge me $10,000 a quarter for this medication called Droxodopa. All right, Landon, let me check.

You have no idea what you're going to pay. If you get it from Cost Plus Drugs, depending on the number and the strength, it might be $21 to $30. There's another drug, Droxodopa. One of my buddies came to me and said, I'm losing my insurance. They want to charge me, the pharmacy wants to charge me $10,000 a quarter for this medication called Droxodopa. All right, Landon, let me check.

Then initially it was $64 a month. Now it's in the $20 per month because as our cost goes down, we pass it on. And That's just changed the industry because think about what happens when you get a prescription.

Then initially it was $64 a month. Now it's in the $20 per month because as our cost goes down, we pass it on. And That's just changed the industry because think about what happens when you get a prescription.

So it's the innovator's dilemma. They can't just give up all of this margin. So most of the business of pharmacy benefit management, not most, a big chunk of the businesses comes from corporations and self-insured companies. And they go to them and they put together the thing called the formulary, which is all the drugs that's available to them. And

So it's the innovator's dilemma. They can't just give up all of this margin. So most of the business of pharmacy benefit management, not most, a big chunk of the businesses comes from corporations and self-insured companies. And they go to them and they put together the thing called the formulary, which is all the drugs that's available to them. And

They say, we're going to price this so that we get rebates and we'll pass on the rebates we get from the manufacturers to you. Now, they say they're going to pass on 100% of that rebate. They don't. They create all these subsidiaries and everything that skim 10% or whatever off the top.

They say, we're going to price this so that we get rebates and we'll pass on the rebates we get from the manufacturers to you. Now, they say they're going to pass on 100% of that rebate. They don't. They create all these subsidiaries and everything that skim 10% or whatever off the top.

But they know that they can continue working with these companies because the core competency of a CEO is not to know their health care costs. And literally for any CEOs that are out there, audit your PBM contract. Audit it right now. I promise you that that PBM is going to tell you you don't need to audit. And then you can say, we want to add cost plus drugs to our pharmacy supply contract.

But they know that they can continue working with these companies because the core competency of a CEO is not to know their health care costs. And literally for any CEOs that are out there, audit your PBM contract. Audit it right now. I promise you that that PBM is going to tell you you don't need to audit. And then you can say, we want to add cost plus drugs to our pharmacy supply contract.

And they're going to say, no, you're not allowed to do it because they know our prices are so much lower that is disrupting their industry.

And they're going to say, no, you're not allowed to do it because they know our prices are so much lower that is disrupting their industry.

Right now, I'm losing money. And most of that was because we built a factory, a whole robotics driven factory that manufactures sterile injectables that are in short supply.